Skip to content
1st Counsel – Lifestyle
Author:
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
October 2, 2026
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
October 1, 2026
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
September 23, 2026
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Artiva Biotherapeutics: AlloNK Phase 3 RA Trial & 2026 Data Updates
September 8, 2026
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
September 2, 2026
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 6, 2026
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 23, 2026
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
June 8, 2026
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
1
2
Next Page
→